Becton Dickinson stock holds near its yearly high

Becton Dickinson stock (US0718131099) traded at USD 188.13 on September 1, 2026, while the latest quarterly update showed Q3 fiscal 2026 revenue of USD 5.0 billion and adjusted EPS of USD 3.23. The shares also stood just below the 1-year high of USD 193.07 and above the 1-year low of USD 127.59.

Q3 figures drive the setup

According to a market report dated September 1, 2026, revenue in Q3 fiscal 2026 reached USD 5.0 billion, up 5.4 percent year over year, while foreign exchange neutral growth was 4.4 percent. GAAP diluted EPS from continuing operations was USD 1.64, compared with adjusted diluted EPS of USD 3.23.

The comparison is the key point for investors: adjusted EPS was USD 1.59 above the GAAP figure in the quarter, and the reported revenue crossed the USD 5 billion mark. That gap shows how much non-recurring items still shape the earnings line.

Market value stays high

As of September 1, 2026, the stock carried a market capitalization of USD 51.84 billion and traded 2.5 percent below the 1-year high of USD 193.07. The same snapshot leaves the shares 47.3 percent above the 1-year low of USD 127.59.

Medical devices stay central

Becton Dickinson remains centered on medical technology, with consumables, devices and diagnostics shaping the revenue base behind the quarter. The latest update also listed a quarterly dividend of USD 1.05, with record date September 9, 2026 and payment date September 30, 2026.

Price and profile

As of September 1, 2026, Becton Dickinson stock traded at USD 188.13 on the NYSE. The company is in the Health Care sector, the Medical Instruments and Supplies industry and the S&P 500.

Becton Dickinson facts

• Company: Becton, Dickinson and Company
• ISIN: US0718131099
• Ticker: BDX
• Trading venue: NYSE
• Price (as of September 1, 2026): USD 188.13
• Market capitalization: USD 51.84 billion (as of September 1, 2026)
• Sector / Industry: Health Care / Medical Instruments and Supplies
• Index membership: S&P 500